News

search close

Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

Read more

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

Read more

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

Read more

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021

Read more

Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference

Read more

Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference

Read more

Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

Read more

Relmada Therapeutics to Participate in Upcoming Investor Conferences

Read more

Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones

Read more

Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®

Read more